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 Abstract  The regulation of agricultural plant and microbial biotechnology products 
in the United States of America has a rich history that re fl ects the challenges the 
federal government has faced in the development of appropriate rules and standards 
needed to determine their safety to humans and the environment. Several factors – 
the insuf fi cient global food supply, loss or curtailment of the use of older chemis-
tries to control pests due to risks and environmental persistence, the rising demand 
for safer food commodities, and the uncertainty surrounding the sustainability of 
agriculture in this and other countries – have added to these challenges. The chapter 
introduces the U.S. Coordinated Framework for the Regulation of Biotechnology 
(“Framework”), and the roles of its members: the U.S. Department of Agriculture 
(USDA), the U.S. Food and Drug Administration (FDA), and the U.S. Environmental 
Protection Agency (EPA) in regulating agricultural biotechnology in accordance with 
U.S. federal statutes. The Framework agencies use scienti fi c, risk-based approaches 
in carrying out their regulatory responsibilities for the products of biotechnology. 
Relying on their experiences with risk assessment and risk management policies 
and principles for more conventional products, the Framework agencies have 
adapted new risk and exposure scenarios into their evaluations to ensure the safe use 
of these products in agriculture. 
 Keywords  Biotechnology •  Federal Food, Drug, and Cosmetic Act (FFDCA) 
•  Federal Insecticide, Fungicide, and Rodenticide Act (FIFRA) •  Food Quality 
Protection Act (FQPA) •  Genetically engineered crops •  Plant-incorporated protectants 
•  Plant Protection Act •  Regulated articles •  Regulation •  Toxic Substances Control Act 
(TSCA) •  U.S. Coordinated framework 
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 1.1  Background 
 Regulatory oversight of biotechnology has been in place in the United States (U.S.) 
since the 1970s, although early guidance documents did not truly have the regu-
latory teeth to adequately handle the oversight of all the organisms being engineered 
for research or commercial purposes (Pizzuli  1984 ) . Since those early days, the 
regulatory system in the U.S. has developed and adapted as needed to regulate 
microbes, plants, fungi and animals as products of biotechnology for environmental 
release and commercialization. For example, genetically engineered (GE) crops 
have been rapidly adopted in the U.S. with about 94% of soybeans, 90% of cotton, 
88 % of  fi eld corn, and 55 % of canola acreages being derived from rDNA 
techniques (ERS  2011 ; Fig.  1.1 ). The percent adoption of other GE crops, such as 
sugarbeet and alfalfa, has also increased with no evidence that this trend will not 
continue in the U.S. and elsewhere (ISAAA  2012 ) . The signi fi cant adoption of GE 
crops re fl ects a functioning U.S. regulatory system. 
 Disclaimer 
 The content of this chapter re fl ects the opinions of the authors and this chapter 
is not intended to constitute a statement of the of fi cial policy or actions of the U.S. 
Environmental Protection Agency. 
 Fig. 1.1  Growth in adoption of genetically engineered crops continues in the U.S.  HT = Herbicide 
tolerant,  Bt = Expressing an insecticidal protein from  Bacillus thuringiensis 
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 The purpose of this chapter is to elucidate the historic guidance, regulations, and 
procedures that govern experimentation with genetically engineered (GE) organisms in 
experimental  fi eld trials and uncon fi ned environmental release of GE organisms. 
The safety assessment of genetically engineered food will also be brie fl y discussed. 
All of the information for this analysis was obtained from publicly available 
sources provided by the respective regulatory authorities and the primary literature. 
The other focus of this document is the Coordinated Framework for Regulation of 
Biotechnology, a policy document regarding regulation of biotechnology products 
which was published by the Of fi ce of Science and Technology Policy (OSTP) in 
1986 (OSTP  1986 ) . The Framework involves key roles for the U.S. Environmental 
Protection Agency (EPA), the U.S. Department of Agriculture, Animal and Plant 
Health Protection Service (USDA-APHIS), and the U.S. Food and Drug Administration 
(FDA). This chapter restricts its focus to regulation of GE microbes and plants, while 
other chapters in this book examine regulation of insects and vertebrate animals. 
 While this book re fl ects the application of recombinant DNA (rDNA) to the genetic 
engineering of organisms, the term ‘biotechnology’ can be viewed more broadly to 
re fl ect the application of biology to man’s needs and desires. This is especially important 
when making the distinction between ‘genetically engineered’ organisms and the more 
general term ‘products of biotechnology’ or ‘genetically modi fi ed’ (GM). It is worth 
noting that all crops plants domesticated for use by man have been modi fi ed genetically 
through selection and plant breeding practices. However, for the purposes of this chapter 
and the majority of this book, we will reserve the term as applicable to products and 
processes derived from the use of rDNA. 
 Microbial biopesticides have been regulated under FIFRA since 1948 (e.g., 
 Bacillus popillae ) and genetically engineered microbial pest control agents 
(MPCA) since the mid-1980s using the same statutory authority with regulations 
(40 CFR 158.2100) modi fi ed and updated over time (see Chap.  4 for more detail). 
It is important to note that the same regulations and data requirements were applied 
to both GE and non-GE MPCAs . With the advent of  in planta expression of pesti-
cidal substances in the late 1980s, thus creating plant-incorporated protectants 
(PIPs), regulations were again updated to re fl ect the novelty of these pesticides 
(EPA  1994,  2001b ) . Technological developments take time and regulations must 
remain dynamic and  fl exible in order to keep pace with the technology (Jepson  2003 ) . 
This is certainly the case with agricultural biotechnology. 
 1.2  Early Regulatory Development for Biotechnology Products 
 For centuries, humans have improved crop plants through selective breeding and 
hybridization — largely through the controlled pollination of plants. Meiotic 
recombination following pollination that may include undesirable traits which 
have to be bred out of the new plant by multiple backcrosses before a hybrid can 
become a commercially viable new variety. In more recent times, plant breeders 
created new varieties using chemicals or irradiation to provide unique traits in 
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plants via mutagenesis. Plant transformation is a form of plant breeding with one 
very important difference — plant biotechnology allows for the transfer of speci fi c 
genetic information from species related or unrelated to the plant with modi fi cations 
to the expression pattern of these transgenes in both a temporal and spatial 
manner. 
 Traditional plant breeding involves the crossing of thousands of genes, whereas 
plant biotechnology allows for the transfer of only one or a few desirable genes. 
 Responding to the rapid increase in the production of biotechnology products, there 
was a realization of the need for some sort of guidance to ensure that public health and 
the environment are adequately protected from the potential risks of this technology. 
As products began moving from the laboratory toward the market, scientists and 
regulatory agencies realized that there should be regulatory mechanisms to ensure 
that these new products did not adversely affect public health or the environment 
(Howland  1987 ) . To clarify regulatory jurisdiction over biotechnology products, the 
Reagan Administration established an interagency working group under the White 
House Cabinet Council on Natural Resources and the Environment (now known as the 
Domestic Policy Council) in 1984 and the Biotechnology Science Coordinating 
Committee in 1985 (Patterson and Josling  2001 ) . The working group’s principle goal 
was to ensure the regulatory process adequately considered health and environmental 
safety consequences of the products of biotechnology as they move from the 
laboratory to the marketplace. Safety was not their only concern; however, as the 
Council also emphasized the importance of not sti fl ing innovation or enervating 
the competitiveness of the U.S. biotech industry. Thus, the interagency working 
group sought to establish a sensible framework that effectively protected human health 
and the environment while providing breathing room for a burgeoning industry. 
Scientists also wanted the freedom and  fl exibility to engage in research and did not 
want Congress to pass unduly restrictive laws (Mandel  2006 ) . 
 The U.S. Federal government set forth its policy statement on the regulation of 
agricultural biotechnology in a document entitled the Coordinated Framework for 
Regulation of Biotechnology (OSTP  1986 ) . This publication in the Federal Register 
established the regulatory roles for Executive Branch agencies in ensuring the safety 
of biotechnology research and products for human health and the environment, and in 
addressing a previous policy proposal promulgated in 1984 with the same title 
(OSTP  1984 ) . A 2 year public comment period helped to shape this policy statement 
in its evolution to the  fi nal 1986 publication. The working group formed under the 
OSTP concluded that the existing statutes and administrative agencies would be 
adequate for the regulation of biotechnology as long as they were under a common 
framework (Stepp  1999 ) . The Coordinated Framework for the Regulation of 
Biotechnology set forth policy directing the oversight of biotechnology under EPA, 
USDA, FDA, NIH, the National Science Foundation (NSF), and the Occupational 
Safety and Health Administration (OSHA) dependent on the type of genetic 
modi fi cation under development. The Framework also established a Biotechnology 
Science Coordinating Committee to ensure timely and coordinated regulatory decision 
making, interagency communication, discuss jurisdiction over products of biotech-
nology, and to keep track of the changing scene in biotechnology (Stepp  1999 ) . 
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 The Coordinated Framework was guided by several principles, including the 
concept of a case-by-case review of new products, assessing the risk associated with 
the product and not the process itself, and that genetically engineered organisms do 
not differ fundamentally from their non-GE counterparts (i.e., the same parameters 
of biochemistry, genetics and physiology apply to all organisms regardless of origin). 
It was further anticipated that the technology would evolve and regulations, as well 
as administrative procedures, would also need to evolve to adapt to novel products 
of biotechnology (OSTP  1986 ) . It was noted early on, however, that both pesticidal 
and non-pesticidal microorganisms would require further regulatory re fi nement as 
compared to other organisms known at the time the Framework was released to 
the public. 
 As a result of existing statutory mandates and regulatory history, three agencies 
were selected to oversee the primary regulation of agricultural biotechnology: the 
U.S. Department of Agriculture, Animal and Plant Health Inspection Service 
(USDA-APHIS), the Environmental Protection Agency (EPA), and the Food and 
Drug Administration (FDA). With each agency regulating products of biotechnol-
ogy under separate statutory mandates, the individual product may be regulated by 
more than one agency (Table  1.1 ). It is important to remember that each agency will 
view the product differently based upon their statutory responsibilities. These regu-
latory triggers will be explained in the sections below dealing with individual agency 
oversight. While not discussed herein, States may also regulate these products under 
their laws beyond the realm of Federal mandates. 
 The  fi rst approved environmental release of a GE organism occurred in 1987 
following the approval by the National Institutes of Health (NIH) and the U.S. 
Environmental Protection Agency (EPA). This  fi rst release was a  fi eld test of 
“ice-minus” bacteria used for preventing frost damage on strawberries ( Marchant 
 1988 ). These were strains of  Pseudomonas syringae and  Erwinia herbicola with 
mutations in a gene encoding an ice-nucleation protein that is normally expressed 
on the bacterial cell surface, but not in “ice-minus” strains. This approval 
sparked a heated controversy, including several court cases, challenging the 
NIH decision and questioning the ability of federal agencies to address hazards 
to ecosystems in light of the uncertainties (Wrubel et al.  1997 ) . Although this 
ice-minus phenotype is outside the normal scope of EPA oversight related to 
pesticides, the controversy erupting publically when the test was  fi rst proposed 
in 1984 and the lack of an established regulatory framework for GE organisms 
at that time led to EPA becoming the default agency for oversight (Bill Schneider, 
EPA, personal communication,  2011 ). 
 This chapter and many others in this book deal with the primary statutes which 
grant authority to Federal agencies for oversight of biotech products. It is at least 
worth mentioning that many other statutes may play a role in regulation of biotech 
products in speci fi c instances at both the Federal and State levels. For example, the 
National Environmental Policy Act is signi fi cant in the regulatory process at USDA-
APHIS and FDA (Belson  2000 ; Mandel  2006 ) . The Endangered Species Act is also 
considered as part of the risk assessment process for USDA-APHIS, EPA and FDA 
when making environmental risk management decisions. Additionally, individual 
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states may require more restrictive regulations for biotech products as they deem  fi t 
(Beachy et al.  1996 ). A further discussion of these statutes in fl uencing oversight can 
be found in the OSTP archived biotech case studies ( OSTP  2001a ). 
 1.3  Coordinated Federal Framework 
 Biotech crops undergo a food safety and environmental review process conducted 
by the FDA, the EPA, and the USDA-APHIS. Each agency operates under their 
respective laws and regulations with some statutory overlap. The three agencies 
routinely interact while regulating GE organisms and make an effort to keep each 
other apprised of regulatory  fi ndings and decisions. Additionally, the OSTP oversees 
the Agricultural Biotechnology Working Group (ABWG), consisting of members 
from the regulatory agencies as well as several other Executive branch agencies. 
The purpose of the ABWG meetings is to ensure coordination among the U.S. 
 Table 1.1  Oversight of genetically engineered plants and traits in the US 
 Trait phenotype/crop  Agency  Statutory authority a 
 Disease/insect resistance 
in food or feed crop 
 USDA-APHIS  Plant Protection Act – plant pests, 
weeds and environmental effects 
 EPA/US FDA b 
 FIFRA/FFDCA – PIP pesticides; 
environmental, food and feed safety 
 FFDCA – food and feed safety 
 Herbicide tolerance 
in food or feed crop 
 USDA-APHIS c 
 EPA d 
 FDA 
 Plant Protection Act – plant pests, 
weeds and environmental effects 
 FIFRA/FFDCA – herbicide 
use on crop; environmental 
effects, food and feed safety 
of herbicide residues 
 FFDCA – food and animal feed safety 
 Herbicide tolerance 
in ornamental/
non-food crop 
 USDA-APHIS 
 EPA 
 Plant Protection Act – plant pests, 
weeds and environmental effects 
 FIFRA – herbicide use on crop, 
environmental effects 
 Quality enhancement traits 
for food or feed crop 
 USDA-APHIS 
 FDA 
 Plant Protection Act – plant pests, 
weeds and environmental effects 
 FFDCA – food and feed safety 
 Flower color enhancement 
in a non-food crop 
 USDA-APHIS  Plant Protection Act – plant pests, 
weeds and environmental effects 
 
a
 Primary statutory authority, however, other statutes may apply under certain circumstances. It should 
be noted that all agencies involved are subject to the provisions of the Endangered Species Act 
 
b
 FDA oversight may be voluntary consultation when trait is not a food additive 
 
c
 PPA requires an assessment of the GE crop to act as a plant pest as de fi ned in 7CFR Part 340 
 
d
 EPA does not regulate the HT crop plant, only the use of the herbicide, and its residues on the crop 
and potential non-target effects from the use of herbicide in a cropping situation 
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Federal government, and to provide a forum for open and free exchange of ideas, 
relative to the policy, regulation and use of biotech derived products in agriculture. 
 Brie fl y, each agency’s roles are as follows 1 :
 • The USDA-APHIS protects agriculture and the environment from pests, diseases, 
and weeds. 
 • The EPA protects human health and the environment, using the standard of no 
unreasonable adverse effects upon man and the environment, as it evaluates 
plant-incorporated protectants, microbial pesticides, and intergeneric 
microorganisms. 
 • The FDA protects the safety of the food and feed supply. 
 1.3.1  Role of the Animal and Plant Health Inspection Service 
 USDA-APHIS is responsible for protecting the United States’ animal and plant 
resources from agricultural pests and diseases. Under the authority of the Plant 
Protection Act (June 20, 2000), APHIS regulations (7 CFR 340) provide procedures 
for obtaining a permit or for submitting a noti fi cation, prior to “introducing” a regulated 
article in the United States. A genetically engineered organism is considered a 
regulated article if the donor organism, recipient organism, vector or vector agent 
used in engineering the organism belongs to one of the taxonomic groups listed in 
the regulation and is also a plant pest, or if there is a reason to believe it is a plant 
pest (USDA-APHIS 2001). 
 The act of introduction includes any movement into (import) or through (inter-
state) the United States, or release into the environment outside an area of physical 
con fi nement. The regulations also provide for petitions for the determination of 
nonregulated status. Once a determination of nonregulated status is granted, the 
product (and its offspring) no longer requires APHIS review for movement or 
release in the United States. Transgenic plants that have been genetically engineered 
to express insecticidal proteins are considered regulated articles by APHIS unless 
and until they are granted non-regulated status through the petition process. 
 Unlike regulatory licensing as practiced under FIFRA by EPA, once GE organ-
isms successfully complete a deregulation process, they are no longer subject to 
oversight by USDA-APHIS (Mandel  2006 ) , although they may still be regulated 
under FIFRA if they are PIPs. Deregulated GE plants become nonregulated and are 
not required to submit yearly reports on sales or distribution to USDA-APHIS as 
they would be required to submit to EPA if they were registered as a PIP. 
 APHIS regulations part 7 CFR 340.6 (c)(4) describe the types of data and infor-
mation that a developer must submit in support of a petition for nonregulated status. 
 1  http://www.aphis.usda.gov/publications/biotechnology/content/printable_version/BRS_
CoordFrameBro.pdf 
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In part, these speci fi cally include under a description of “known and potential 
differences from the unmodi fi ed recipient organism that would substantiate that the 
regulated article is unlikely to pose a greater plant pest risk than the unmodi fi ed 
organism from which it was derived,” including effects of the regulated article on 
non-target organisms and indirect plant pest effects on other agricultural products 
and, under 7 CFR 340.6 (c) (5), data reports from  fi eld trials conducted under APHIS 
permit or noti fi cation that shall include “methods of observation, resulting data, and 
analysis regarding all deleterious effects on plants, nontarget organisms, or the 
environment.” 
 Since the PPA relies on the determination of plant pest or noxious weed status as 
a trigger to regulation of GE organisms, and plant pests are de fi ned rather broadly 
therein as essentially any organism causing harm to a plant or plant parts (Belson 
 2000 ) , even the use of a plant pest (e.g.,  Agrobacterium tumefaciens ) or a plant pest 
sequence (e.g., CaMV 35S promoter) as part of the transformation process may 
deem the resultant product a regulated article and under the oversight of USDA-
APHIS. Interestingly, some plants engineered for herbicide tolerance while 
attaining the status of a noxious weed were not ultimately regulated under PPA as 
they were found to lack any plant pest sequences and no plant pest organism was 
used in their construction (USDA-APHIS  2011a,  b ) . 
 1.3.2  Role of the U.S. Environmental Protection Agency 
 The EPA regulates pesticides under the Federal Insecticide, Fungicide and Rodenticide 
Act (FIFRA). This Act requires that all pesticides sold or distributed in the United 
States must be registered with the EPA unless they are speci fi cally exempted. The EPA 
also regulates the amount of pesticide residue that can be in or on the speci fi c 
agricultural commodity the food or feed supply under the Federal Food, Drug, and 
Cosmetic Act (FFDCA). Most of this law is the purview of FDA, but the pesticidal 
authority to establish tolerances or exemptions from the requirement of a tolerance 
rests with EPA. FDA does maintain enforcement authority under FFDCA in cases 
where an illegal pesticide residue persists on a food or feed product. 
 EPA also regulates intergeneric microorganisms, under the Toxic Substances 
Control Act (TSCA) section 5, that are not covered by other statutes and are manu-
factured, imported, or processed for commercial purposes. Agricultural purposes 
can include biofertilizers (e.g., nitrogen  fi xers, mycorrhizae, phosphate solubilizers, 
etc.), algal biofuels, pesticidal intermediates, and perhaps, biosensors. Under the 
Coordinated Framework, EPA promulgated regulations for intergeneric microor-
ganisms under TSCA which were  fi nalized in 1997 (see Chap.  4 for greater detail). 
 Regulations for Biotechnology Noti fi cation prior to small scale  fi eld testing of 
engineered microbial pesticides were  fi nalized in 1994 and existing regulations for 
PIPs were  fi nalized in 2001. Chapter  4 in this volume contains further details on 
FIFRA and TSCA regulation of microbes and Chap.  10 details the regulatory 
requirements for PIPs under FIFRA and FFDCA. 
91 An Introduction to Agricultural Biotechnology Regulation in the U.S.
 Microbial pesticides can be naturally occurring or genetically engineered. 
Genetically engineered microorganisms are regulated using the same data 
requirements used for naturally occurring microbial pesticides (See 40 CFR part 
158.740). Additional information may be required concerning the genetic engi-
neering process used and the results from that process, however, the toxicity and 
pathogenicity evaluation is identical to that used to assess the non-GE counterpart 
MPCA. EPA requires a Biotechnology Noti fi cation be issued prior to small scale 
 fi eld testing of genetically engineered microorganisms at any size of environmental 
release to allow EPA to determine if an Experimental Use Permit is needed (See 40 
CFR part 172 subpart C). When testing 10 A or more terrestrially or 1 A aquatically, 
EPA requires an Experimental Use Permit before  fi eld testing naturally occurring or 
genetically engineered microorganisms when used as microbial pest control agents 
(MPCA). Under FIFRA, microbial biotech products, as with all other pesticides, must 
be evaluated for their risks and bene fi ts. Before any registration is granted, OPP 
considers such issues as potential adverse effects to non-target organisms, environmental 
fate of the microorganism, and the potential pathogenicity and infectivity of the 
microorganism to humans and other animals. 
 PIPs are de fi ned as pesticidal substances “intended to be produced and used in a 
living plant, or in the produce thereof, and the genetic material necessary for the 
production of such a pesticidal substance”. The PIP also includes any inert ingredient 
contained in the plant, or produce thereof (40 CFR 174.3). Inert ingredients may 
include herbicide tolerance traits and antibiotic resistance markers when they are 
used in the development of a PIP product. PIPs are regulated under FIFRA as pesticides 
and require a tolerance exemption or exemption from the requirement of a tolerance 
under FFDCA when the PIP is expressed within a food or feed crop (Table  1.1 ). The 
genetic material necessary for the production of such a pesticidal substance also 
meets the FIFRA statutory de fi nition of a pesticide because such genetic material is 
introduced into the plant with the intent of ultimately producing a pesticidal effect 
even though the genetic material may not, itself, directly affect pests. Both the 
insecticidal protein and its genetic material are regulated by EPA; the plant itself is 
not regulated by EPA. This is a key distinction between PIP regulation by EPA and 
regulation of GE crops by USDA-APHIS and FDA. 
 EPA also issues experimental use permits (EUPs) for  fi eld trials of PIPs that are 
more than 10 acres cumulative area across the United States when targeting a single 
pest or pest complex.. These EUPs are intended to serve as a mechanism to collect 
 fi eld data in support of an eventual Section 3 registration. The 10 acre cutoff for 
regulatory oversight is based upon the concept that a small acreage results in a small 
overall environmental exposure and is, therefore, not likely to result in an adverse 
effect upon the environment. It should also be noted that in most instances, the 
USDA-APHIS is regulating the  fi eld trials at any size area under a permitting 
system. However, if the PIP could be in the food or feed supply or be fed to animals 
which would enter the food supply at less than 10 A area of  fi eld testing, then a 
tolerance or tolerance exemption must be obtained before  fi eld trials are performed 
regardless of whether an EUP is required or not. A company may choose to test 
several closely related transformation events under one EUP, but a commercial 
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registration would only be for a PIP resulting from a single transformation event 
(EPA  2011a ) . 
 PIPs are pesticides and are therefore regulated under FIFRA. Under FIFRA 
Section 3, EPA registers PIPs to be sold and distributed with the consequent regula-
tions under 40 CFR. EPA evaluates each PIP application to determine whether its 
proposed use would cause unreasonable adverse effects on man and the environment. 
In order to avoid potential unreasonable adverse effects, the Agency may impose 
(and has imposed) conditions on registration of PIPs (e.g., conditions to slow or 
eliminate insect resistance; EPA  2001a ) . When the PIP expressing plant may enter 
the food or feed stream, FFDCA section 408 is also applicable to the PIP crops or 
human food or animal feed products derived from them. 
 Under FFDCA, EPA establishes tolerances, or in the case of the PIPs registered 
to date, tolerance exemptions, wherein no numerical maximum level or quantity of 
the pesticidal substance residue is denoted. Such exemptions from the requirement 
of a tolerance are based upon the absence of adverse toxicological outcomes during 
acute toxicity testing. EPA evaluates each PIP application to determine whether 
dietary exposure to the residue of any PIP in food or feed is safe, i.e., whether that 
there is a reasonable certainty of no harm resulting from aggregate exposure to the 
pesticide, which includes all anticipated dietary exposures and all other exposures 
for which there is reliable information. The tolerance exemptions issued allow PIPs 
to be used in foods with a reasonable certainty of no harm. Due to the ubiquitous 
nature of nucleic acids in food and feed, and the lack of demonstrable toxicity from 
their consumption, all nucleic acids as present within PIPs are exempted from the 
requirement of a tolerance under FFDCA. 
 Based on laboratory studies,  fi eld trials, and other information, EPA scientists 
assess a wide variety of potential effects associated with the PIP. These areas will be 
discussed in Chaps.  10 ,  11 and  12 according to scienti fi c discipline. 
 EPA considers public comments for PIP regulatory actions and often holds 
FIFRA-proscribed Scienti fi c Advisory Panel meetings charging outside experts to 
peer review EPA’s risk assessments, when EPA identi fi es speci fi c scienti fi c questions 
or concerns that need additional consideration (EPA  2011b ) . All public comments 
are reviewed for their potential impact upon decision making (i.e., risk management) 
and responded to publically. Time frames and fees for EPA pesticide registration 
decisions vary based on the type of action. EPA uses a fee-for-service system 
associated with its pesticide registrations and experimental use permits under the 
Pesticide Registration Improvement Act (PRIA) of 2004, as amended. Under PRIA, 
an applicant pays a fee according to the speci fi cs of the regulatory action sought 
(e.g., EUP, registration, tolerance) and receives a de fi nitive timeline for decision 
making. Fees vary by action and portions of the fee may be waived depending on 
the af fi liation of the applicant; researchers associated with a government agency 
will have all fees waived, those from universities or small companies may have a 
portion waived and those from large companies (i.e., >500 employees) will generally 
not receive a waiver. This fee for service approach is in contrast to FDA and USDA-
APHIS who do not charge fees for reviews or consultations regarding GE microbes 
or plants. 
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 1.3.3  Role of the Food and Drug Administration 
 The Food and Drug Administration uses the food safety and food additive authorities 
in the Federal Food, Drug and Cosmetic Act of 1938 (FFDCA), as amended, to 
regulate the safety of biotech foods. Under these laws, FDA operates a voluntary 
premarket noti fi cation and consultation system that provides biotech companies an 
opportunity to demonstrate that foods produced from their biotech crop are as safe 
as their traditional counterparts. 
 If biotech food contains a protein or other new substance that is not “generally 
recognized as safe” (GRAS), the food must go through a formal FDA premarket 
approval process in which the sponsor must prove scienti fi cally that the new sub-
stance in the food is safe. Note that the new substance does not include pesticides, 
which are regulated by EPA, but rather something like a modi fi ed oil pro fi le or a 
protein altered such that it is no longer an allergen. 
 FDA’s oversight of biotech foods is managed through the Division of 
Biotechnology and GRAS Notice Review, Of fi ce of Food Additive Safety, in FDA’s 
Center for Food Safety and Applied Nutrition (CFSAN), which coordinates reviews 
with FDA’s Center for Veterinary Medicine (CVM). CFSAN regulates GE crop 
plants which are not PIPs and contain food additives (FDA  1997,  2005a ) , whereas 
CVM regulates GE animals containing new animal drugs (OSTP  2001b ) . 
 In 1992, the FDA issued a policy statement regarding how the agency intended 
to regulate human foods and animals feeds derived from new plant varieties, including 
varieties developed using DNA technology, which were referred to as “bioengineered 
foods.” In general, the FDA announced that bioengineered foods would be regulated 
no differently than foods developed through traditional plant breeding. As a class, 
bioengineered foods did not require special labeling nor were they subject to 
premarket approval. The FDA looks to the objective characteristics of the food 
and its intended use, not the method by which the food was developed. 
 The FDA also acknowledged the food industry’s long-standing practice of 
consulting with the FDA in the early stages of developing food through new 
technologies. This practice, although not required, allows the agency to identify 
and address issues regarding foods and food ingredients before they are marketed. 
The FDA expressed its expectation that such consultation would continue with 
regard to bioengineered foods. In 1997, the FDA issued guidance on procedures for 
these consultations (FDA  1997 ) . 
 A company that intends to commercialize a bioengineered food meets with the 
FDA at an “initial consultation” to identify and discuss possible issues regarding 
safety, nutritional, or other regulatory issues. A “ fi nal consultation” is held once the 
company believes it has developed the data and information necessary to address 
issues or concerns raised by the FDA. 
 The FDA consultation process does not constitute a formal review, as would 
occur with a food additive for example, but rather it is a voluntary consultation. 
During this iterative process, the FDA Center for Food Safety and Applied Nutrition 
performs a comparative assessment of the composition of the GE crop and its non-GE 
12 C.A. Wozniak et al.
counterpart (FDA  1997 ) . In instances where the proximate analysis and the 
examination of allergens and anti-feedants suggests that there is no signi fi cant 
difference between the GE and non-GE counterparts, the FDA indicates that it has 
no further questions regarding the use of this food or feed product in commerce, but 
it remains the responsibility of the manufacturer to ensure the safety of the food or 
feed product (Belson  2000 ) . This  fi nding by the FDA, while made on a voluntary 
basis, indicates that the GE food or feed product is ‘as safe as’ its non-GE counter-
part. The agency does not deem a GE food or feed crop as ‘safe’ per se. To date, all 
GE food and feed products have undergone a consultation with FDA CFSAN prior 
to marketing even though the process is voluntary. The Flavr Savr™tomato was the 
 fi rst commercialized GE food crop and the only one to date to undergo formal 
review by FDA as a food additive, at the request or insistence of the developer 
Calgene (FDA  2005b ) . This review considered the presence of the neomycin 
phosphotransferase enzyme in the food product as this enzyme was used as a 
selectable antibiotic resistance marker in the development of the product. 
 1.4  Trends 
 The U.S. regulatory system has matured over the last 30 years by remaining adapt-
able and  fl exible as well as by being responsive to input from stakeholders. Following 
advances in molecular biology and rDNA techniques in the 1970s, genetic engineering 
of microbes, then plants, soon followed. As with most new technologies, a level of 
uncertainty led to apprehension among scientists and the general public once 
applications of biotechnology were becoming a reality (Pizzuli  1984 ; Grif fi n  1988 ) . 
The Asilomar Conference in 1975 served to address some of these concerns although 
not all attendees were in agreement on how products of biotechnology should be 
regulated and by whom (Howland  1987 ; Marchant  1988 ; Barinaga  2000 ) . 
 Following the establishment of the Coordinated Framework for Regulation of 
Biotechology in 1986, the role of the three principal regulatory agencies was 
somewhat clearer, however, the three agencies needed to further develop policies 
and practices. This was only the beginning. Guidance documents promulgated by 
regulatory agencies started to take shape, but these are an ongoing process to this 
day as they continue to respond to advances in biotechnology. 
 One of the authors recalls that in the late 1980s and early 1990s, even simple 
experiments with recombinant plasmids performed in debilitated laboratory strains 
of  E. coli (e.g., K-12) triggered a laboratory inspection by both the USDA-APHIS 
and local university Institutional Biosafety Committee representative. Adherence to 
the NIG Guidelines (NIH  1976 ) was agreed to laboratory access limited in terms of 
public invitations for tours. Following applications to USDA-APHIS to receive 
strains of  Agrobacterium to be used in transformation protocols, laboratory and 
growth room facilities were inspected and later audited to ensure all GE materials 
were kept con fi ned under lock and key and uninvited personnel could not gain 
access to these tissue cultures bacterial stabs! Instructions were also given to placard 
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the doors and refrigerators with biohazard insignias. Transgenic cotton plants were 
not allowed in the university greenhouse, but had to be keep in a locked storage 
room out fi tted with high intensity lamps! Early measures were rather cautious to 
say the least. We have come a long way since 1987. 
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